Suchergebnisse - "Molife, L R"

PubPharm (13)

1

Antitumor activity of ipatasertib combined with chemotherapy : results from a phase Ib study in solid tumors

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von Isakoff, S. | Tabernero, J. | Molife, L. | +18

2

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

enthalten in: Targeted oncology | 2016

von Mateo, J. | Moreno, V. | Gupta, A. | +15

3

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation : a multistudy analysis of response rates and safety

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Matulonis, U. | Penson, R. | Domchek, S. | +10

4

Phase I trial outcomes in older patients with advanced solid tumours

enthalten in: British journal of cancer | 2016

von Khan, K. | Yap, T. | Ring, A. | +9

5

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

enthalten in: British journal of cancer | 2015

von Geuna, E. | Roda, D. | Rafii, S. | +9

6

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2013

von Sandhu, S. | Omlin, A. | Hylands, L. | +21

7

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents

enthalten in: British journal of cancer | 2012

von Moreno Garcia, V. | Thavasu, P. | Blanco Codesido, M. | +9

8

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents : a single centre experience

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2012

von Molife, L. | Alam, S. | Olmos, D. | +8

CommentIn: Ann Oncol. 2012 Aug;23(8):1934-6. - PMID 22510374

9

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2012

von de Bono, J. | Molife, L. | Sonpavde, G. | +10

10

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2012

von Arkenau, H. | Plummer, R. | Molife, L. | +9